• 【作者單位】1.四川大學(xué)華西醫(yī)院普外科（成都 610041）;;
  • 2.四川大學(xué)華西醫(yī)院消化內(nèi)科;

目的觀察臨床常用的免疫抑制劑對急性胰腺炎時炎癥相關(guān)性細胞因子紊亂的調(diào)節(jié)作用，并探討免疫抑制劑治療胰腺炎的效果和機理。方法實驗用雄性SD 大鼠38只, 共分6組： 正常對照組（n=6）； 胰腺炎組 (n=8)，采用開腹胰管注射5%牛磺膽酸鈉制備急性胰腺炎動物模型； 余下4組（均為n=6）在胰腺炎誘導(dǎo)成功后0.5 h按靜脈注射藥物不同分為: 5Fu治療組、甲基強的松龍治療組、環(huán)磷酰胺治療組及氨甲碟呤治療組。手術(shù)后24 h處死動物，分別檢查血中TNFα、IL1、IL6、IL10、TGFβ及胰淀粉酶和胰腺濕重。結(jié)果在急性胰腺炎時，動物血中的炎癥性細胞因子和抗炎癥細胞因子均顯著增高，在使用免疫抑制劑治療后，上述細胞因子均有不同程度下降。其血胰淀粉酶和胰腺濕重也明顯好轉(zhuǎn)。 結(jié)論免疫抑制劑可以抑制急性胰腺炎時異常增高的炎癥細胞因子和抗炎癥細胞因子。通過矯正免疫異常的方式緩解胰腺炎所致的病理生理紊亂，達到治療急性胰腺炎的目的。

引用本文： 陳曉理,黃興蘭, 吳浩, 吳曉娟. 常用免疫抑制劑對急性胰腺炎免疫異常的調(diào)節(jié)作用. 中國普外基礎(chǔ)與臨床雜志, 2002, 9(6): 384-387. doi: 復(fù)制

1. de Beaux AC, Ross JA, Maingay JP, et al. Proinflammatory cytokine release by peripheral blood mononuclear cells from patients with acute pancreatitis [Ｊ]. Br J Surg， 1996; 83(8)∶1071.
2. McKay CJ, Gallagher H, Brooks B, et al. Increased monocyte cytokine production in association with systemic complications in acute pancreatitis [Ｊ]. Br J Surg， 1996; 83(7)∶919.
3. de Beaux AC, Goldie AS, Ross JA, et al. Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis [Ｊ]. Br J Surg， 1996; 83(3)∶349.
4. 崔潤林. 5Fu治療急性胰腺炎的初步觀察 [Ｊ]. 實用內(nèi)科雜志， 1983； 3（5）∶246.
5. 譚下宇 . 5氟尿嘧啶配合腹腔引流治療急性胰腺炎的初步體會 [Ｊ]. 中華醫(yī)學(xué)雜志, 1985； 65（12）∶757.
6. Saarrio IA. 5fluorouracil in the treatment of acute pancreatitis [Ｊ]. Am J Surg,1983; 145(3)∶349.
7. Kimura K,Shimosegawa T,Sasano H，et al.Endogenous glucocorticoids decrease the acinar cell sensitivity to apoptosis during cerulein pancreatitis in rats [Ｊ].Gastroenterology,1998; 114(2)∶372.
8. Darville T， Giroir B， Jacobs R. The systemic inflammatory response syndrome (SIRS): immunology and potential immunotherapy [Ｊ]. Infection, 1993; 21(5)∶279.
9. Schlag G, Redl H. Mediators of injury and inflammation [Ｊ]. World J Surg,1996； 20(4)∶406.
10. Dinarello CA， Gelfand JA， Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome [Ｊ]. JAMA,1993; 269(14)∶1829.
11. Iwagaki H，Hizuta A， Uomoto M，et al. Clinical value of cytokine antagonists in infectious complications [Ｊ].Res Commun Mol Pathol Pharmacol, 1997； 96(1)∶25.
12. Artels H, Zantl N, Holzmann B, et al. Special therapeutic approaches for interrupting the cascadefrom SIRS to MOF [Ｊ]. Langenbecks Arch Chir Suppl Kongressbd, 1988; 115∶615.
  1. 1. de Beaux AC, Ross JA, Maingay JP, et al. Proinflammatory cytokine release by peripheral blood mononuclear cells from patients with acute pancreatitis [Ｊ]. Br J Surg， 1996; 83(8)∶1071.
  2. 2. McKay CJ, Gallagher H, Brooks B, et al. Increased monocyte cytokine production in association with systemic complications in acute pancreatitis [Ｊ]. Br J Surg， 1996; 83(7)∶919.
  3. 3. de Beaux AC, Goldie AS, Ross JA, et al. Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis [Ｊ]. Br J Surg， 1996; 83(3)∶349.
  4. 4. 崔潤林. 5Fu治療急性胰腺炎的初步觀察 [Ｊ]. 實用內(nèi)科雜志， 1983； 3（5）∶246.
  5. 5. 譚下宇 . 5氟尿嘧啶配合腹腔引流治療急性胰腺炎的初步體會 [Ｊ]. 中華醫(yī)學(xué)雜志, 1985； 65（12）∶757.
  6. 6. Saarrio IA. 5fluorouracil in the treatment of acute pancreatitis [Ｊ]. Am J Surg,1983; 145(3)∶349.
  7. 7. Kimura K,Shimosegawa T,Sasano H，et al.Endogenous glucocorticoids decrease the acinar cell sensitivity to apoptosis during cerulein pancreatitis in rats [Ｊ].Gastroenterology,1998; 114(2)∶372.
  8. 8. Darville T， Giroir B， Jacobs R. The systemic inflammatory response syndrome (SIRS): immunology and potential immunotherapy [Ｊ]. Infection, 1993; 21(5)∶279.
  9. 9. Schlag G, Redl H. Mediators of injury and inflammation [Ｊ]. World J Surg,1996； 20(4)∶406.
  10. 10. Dinarello CA， Gelfand JA， Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome [Ｊ]. JAMA,1993; 269(14)∶1829.
  11. 11. Iwagaki H，Hizuta A， Uomoto M，et al. Clinical value of cytokine antagonists in infectious complications [Ｊ].Res Commun Mol Pathol Pharmacol, 1997； 96(1)∶25.
  12. 12. Artels H, Zantl N, Holzmann B, et al. Special therapeutic approaches for interrupting the cascadefrom SIRS to MOF [Ｊ]. Langenbecks Arch Chir Suppl Kongressbd, 1988; 115∶615.